IPSEN (OTCMKTS:IPSEY) Stock Rated “Hold” by Sell-Side Analysts

Shares of IPSEN (OTCMKTS:IPSEY) have earned an average recommendation of “Hold” from the seven brokerages that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company.

Several equities analysts have recently commented on IPSEY shares. Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Barclays raised IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Finally, HC Wainwright reissued a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th.

IPSEN Price Performance

Shares of IPSEY stock opened at $41.98 on Monday. The business has a 50-day moving average price of $46.11 and a two-hundred day moving average price of $46.56. IPSEN has a 12-month low of $32.02 and a 12-month high of $51.10.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.